Returns
| Series | 1 week | 1 month | 3 months | 6 months | YTD | 1 year | 3 years (ann.) | 5 years (ann.) | 10 years (ann.) | Since inception (ann.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Market-price return | -1.04% | -13.24% | -9.36% | -3.49% | +0.69% | +0.90% | +7.28% | -5.92% | -1.47% | +0.70% |
| Market-price total return | -1.04% | -13.24% | -6.81% | +2.32% | +10.15% | +13.79% | +21.38% | +5.01% | +8.66% | +10.09% |
| NAV return | -2.37% | -9.49% | -12.30% | -2.18% | -0.58% | +0.24% | +3.04% | -3.82% | -1.22% | +2.19% |
| NAV total return | -2.37% | -9.49% | -9.90% | +3.48% | +8.43% | +12.26% | +15.34% | +6.36% | +8.11% | +11.53% |
Performance through Oct 14, 2026. Price and NAV returns are simple changes; total returns reinvest each distribution at the series value on its ex-date (first observation on/after). Periods of one year or less are cumulative; longer periods are annualised. Series are built from unadjusted prices plus the distribution record so no distribution is counted twice. Corporate actions: the vendor price series is split-adjusted; rights offerings and mergers are not restated — check Corporate Actions.
Growth of $10,000, five years
Risk statistics
| Statistic | Market price | NAV | Specification |
|---|---|---|---|
| Volatility, 1 year | 0.22% | 0.26% | annualised SD of daily total returns, √252 |
| Volatility, 3 years | 0.20% | 0.21% | as above |
| Volatility, 5 years | 0.20% | 0.19% | as above |
| Maximum drawdown, 3 years | -21.15% | -20.26% | peak-to-trough on the total-return index |
| Sharpe ratio, 3 years | 0.84 | 0.61 | excess over FRED DGS3MO (window average) (avg 4.52%), annualised |
| Sortino ratio, 3 years | 1.20 | 0.88 | downside deviation of excess returns |
| Beta vs. benchmark proxy, 3 years | 0.66 | — | SPY (U.S. equity ETF proxy), daily, aligned dates |
| Correlation, 3 years | 0.51 | — | as above |
| Observations (3y) | 751 | — | minimum 60; rankings require 500 |
Market-price and NAV volatility are different quantities and are never mixed. NAV volatility for funds holding stale-marked or illiquid assets can understate economic risk.
CEF Explorer research page for abrdn Healthcare Investors. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.